Inozyme puts faith in Petra Duda as new CMO

USA-based Inozyme Pharma (Nasdaq: INZY), a biopharma developing innovative therapeutics for rare diseases that affect bone health and blood vessel function, has a new chief medical officer (CMO).

Petra Duda (pictured above), who has more than two decades of experience in global clinical development, medical affairs, and regulatory leadership, with deep expertise in rare and ultra-rare diseases, is taking over from the retiring Kurt Gunter, as he transitions to an advisory role.

Prior to joining Inozyme as senior vice president, clinical development in November 2024, Dr Duda was global development lead at UCB (Euronext: UCB), where she oversaw the Zilbrysq (zilucoplan) program and led it through global approvals for generalized myasthenia gravis.